Clinical trials: Urinary Frequency More Than Once at Night
Nocturia
Effect of Hormonal Replacement Therapy on Nocturia in Postmenopausal Women
Aim of this study was to observe The study was adjusted in two parts: PART 1 is a crossectional study in which the prevalance, risk factors and etiology of nocturia among postmenopausal women is assessed.
- Trial name
- HARALD (NCT04433897)
- Testing
- Questionnaire
- Where
- Belgium
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- University Hospital, Ghent
Nocturia
An Extension Study Investigating the Efficacy and Safety of a Fast-Dissolving ("Melt") Formulation of Desmopressin for the Treatment of Nocturia in Adults
The purpose of this study was to investigate the long term efficacy and safety of several doses of the Melt formulation of desmopressin in a broad population of adult patients with nocturia.
- Trial name
- NCT00615836
- Testing
- Desmopressin Melt
- Where
- 73 sites in United States, Canada
- Volunteers
- 554 people
- Sponsor
- Ferring Pharmaceuticals
Lower Urinary Tract Symptoms, Nocturia
Myrbetriq™ (Mirabegron) to Improve Disordered Sleep in Subjects With Lower Urinary Tract Symptoms (LUTS)
The objective of this exploratory pilot study is to assess whether Mirabegron (Myrbetriq™) will improve the quality of sleep and Lower Urinary Tract Symptoms (LUTS) in men and women presenting with LUTS and disordered sleep.
- Trial name
- NCT02410135
- Testing
- Mirabegron
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- Southern Illinois University
Bladder Dysfunction, Neurogenic Bladder Dysfunction
Feasibility Study of Transcutaneous Tibial Nerve Stimulation for Urinary Symptoms in People With Multiple Sclerosis
Neurogenic lower urinary tract dysfunction is common among people with Multiple sclerosis with a pooled prevalence of 68.41% using self-report measures and 63.95% using urodynamic studies.
- Conditions
- Bladder Dysfunction, Neurogenic Bladder Dysfunction, Urinary Incontinence, Urinary Bladder, Overactive
- Trial name
- NCT04528784
- Testing
- Transcutaneous tibial nerve stimulation
- Where
- Ireland
- Volunteers
- 23 people
- Sponsor
- University of Limerick
Nocturia
A Pilot Study to Evaluate PureWick for Nocturia
This is a single-center prospective pilot study of PureWick used as a management for nocturia and reduction of nighttime falls associated with going to the bathroom. Subjects are followed up to 3 months after the intervention.
- Trial name
- NCT05090722
- Testing
- PureWick System
- Where
- 2 sites in United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Northwell Health
Urinary Bladder Overactive, Urinary Bladder Diseases\Urologic Diseases
This Was a Multinational Study Comparing the Efficacy and Safety of Two Medicines , Solifenacin Succinate and Mirabegron Taken Together, or Separately, or a Mock Treatment (Placebo) in Subjects With Symptoms of Overactive Bladder
The purpose of this study was to examine how well two medicines (solifenacin succinate and mirabegron) combined work compared to each medicine alone in the treatment of bladder problems.
- Conditions
- Urinary Bladder Overactive, Urinary Bladder Diseases\Urologic Diseases, Overactive Bladder, Urgency Incontinence
- Trial name
- SYNERGY (NCT01972841)
- Testing
- Solifenacin succinate, Mirabegron
- Where
- 435 sites in United States, Argentina and 40 more
- Volunteers
- 3,527 people
- Sponsor
- Astellas Pharma Europe B.V.
Women, Urinary Incontinence (UI)
Examination of the Effect of Nocturia on Pelvic Floor Symptoms, Sleep Parameters and Quality of Life in Women With Urinary Incontinence
Urinary incontinence (UI), a common issue, is the involuntary leakage of urine that negatively affects individuals socially, physically, and psychologically, leading to a decreased quality of life.
- Conditions
- Women, Urinary Incontinence (UI), Nocturia
- Trial name
- NCT06866834
- Where
- Turkey (Türkiye)
- Volunteers
- 102 people
- Sponsor
- Gulhane School of Medicine
Benign Prostatic Hyperplasia
A Phase 4 Study With Tamsulosin OCAS to Assess Nighttime Voiding.
Randomized, double-blind, placebo-controlled study with two treatment arms (Tamsulosin OCAS 0.4 mg \& placebo). The study comprises a 2-week placebo run-in followed by a 12-week treatment period.
- Trial name
- NCT00379067
- Testing
- Tamsulosin OCAS
- Volunteers
- 882 people
- Sponsor
- Astellas Pharma Inc
Overactive Bladder
Interventional Clinical Trial in Patients in Overactive Bladder With Nocturia in Women
The purpose of the trial is to investigate the efficacy of combining tolterodine and desmopressin compared with tolterodine monotherapy in the treatment of women with overactive bladder with nocturia in terms of reduction of…
- Trial name
- NCT01729819
- Testing
- Tolterodine tartrate extended release capsules, Desmopressin orally disintegrating tablets
- Where
- 24 sites in United States
- Volunteers
- 106 people
- Sponsor
- Ferring Pharmaceuticals